Novo Nordisk A/S (NONOF)
OTCMKTS
· Delayed Price · Currency is USD
69.49
+0.52 (0.75%)
Jul 3, 2025, 1:08 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
7.20
Revenue / Employee
3.92M DKK
Employees
77,349
Market Cap
316.33B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 84.04M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Novo Nordisk News
- 3 days ago - This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk - The Motley Fool
- 3 days ago - India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year - Financial Post
- 3 days ago - Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever - Seeking Alpha
- 3 days ago - Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share - CNBC
- 3 days ago - Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report - Benzinga
- 3 days ago - Major insurance changes are coming to GLP-1 drugs for weight loss. Heres how that could affect patients - Yahoo
- 3 days ago - Insight: How Novo Nordisk misread the US market for its weight loss sensation - Reuters
- 4 days ago - Hims & Hers Health: Buy The Novo Nordisk Drama Dip - Seeking Alpha